- Recommendation ID
- TA217/1
- Question
- Research is needed to generate robust and relevant data on the effects of treating people with Alzheimer’s disease on both short-term and long-term outcomes, disease progression through relevant health states, and quality of life.
- Any explanatory notes
(if applicable) - None.
Source guidance details
- Comes from guidance
- Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
- Number
- TA217
- Date issued
- March 2011
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |